These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10347637)

  • 1. [Primary prevention remains expensive, notwithstanding the consensus on lowering serum cholesterol levels].
    Bonneux L; Barendregt JJ
    Ned Tijdschr Geneeskd; 1999 Apr; 143(15):772-5. PubMed ID: 10347637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO].
    Simoons ML; Casparie AF
    Ned Tijdschr Geneeskd; 1998 Sep; 142(38):2096-101. PubMed ID: 9856223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
    van Hout BA; Simoons ML
    Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of lipid disorders for coronary heart disease prevention according to International Atherosclerosis Society recommendations].
    Idzior-WaluĊ› B
    Przegl Lek; 1999; 56(5):372-6. PubMed ID: 10554575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
    Johannesson M
    Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prevention of cardiovascular disease: cost-effectiveness comparison.
    Franco OH; der Kinderen AJ; De Laet C; Peeters A; Bonneux L
    Int J Technol Assess Health Care; 2007; 23(1):71-9. PubMed ID: 17234019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy.
    Ess SM; Szucs TD
    Ital Heart J; 2001 Mar; 2(3):181-8. PubMed ID: 11305529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach.
    Martikainen JA; Ottelin AM; Kiviniemi V; Gylling H
    Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):265-72. PubMed ID: 17446806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of lipid-lowering treatment according to lipid level.
    Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA
    Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The human and economic costs of undertreatment with statins.
    Durrington P
    Int J Clin Pract; 2002 Jun; 56(5):357-68. PubMed ID: 12137445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
    Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
    Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversies in primary prevention among hyperlipidemic patients.
    McPherson R
    Can J Cardiol; 1999 Apr; 15 Suppl B():16B-19B. PubMed ID: 10350678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol: precursor to many lipid disorders.
    Jones PH
    Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Great discrepancies between European, Dutch and Belgian criteria for the use of statins in the prevention of primary cardiovascular disease in family practice].
    Van Diest E; Stoffelen E; Wydooghe L; Van Duppen D; Seuntjens L; Van der Stuyft P
    Ned Tijdschr Geneeskd; 2001 Feb; 145(8):361-6. PubMed ID: 11257816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
    Sever PS
    Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting risk reduction of coronary disease in patients who are glucose intolerant: a comparison of treatment with fenofibrate and other lipid-modifying agents.
    Haffner SM; Ashraf T
    Manag Care Interface; 2000 Mar; 13(3):52-8. PubMed ID: 11066277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study.
    Jacobson TA; Gutkin SW; Harper CR
    Curr Med Res Opin; 2006 Jun; 22(6):1065-73. PubMed ID: 16846539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease.
    Walshe V; Nash A; Barry M
    Ir Med J; 2006 May; 99(5):144-5. PubMed ID: 16892920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.